This protein can assist consumers worldwide who wish to reduce added sugars in their diets without sacrificing taste or health
Israel-based Amai Proteins, a company focused on designing innovative proteins for consumers and industries, has completed the world’s first double-blind, randomised clinical trial examining the effects of their proprietary hyper-sweet protein, sweelin, on blood glucose and insulin levels in humans.
The study showed that sweelin does not raise blood glucose or insulin levels in healthy adults, even when consumed in quantities equivalent to the sweetness of 75 grams of sugar (in the form of glucose). Although regulatory authorities did not require this study, Amai Proteins chose to conduct it to enhance consumer and market confidence in the safety and health benefits of sweelin. The results provide validated evidence of the positive effects of sweelin on consumer health. This protein can assist consumers worldwide who wish to reduce added sugars in their diets without sacrificing taste or health.
The trial took place at the Phase 1 Clinical Research Center (CRC) of Tel Aviv Sourasky Medical Centre, adhering to strict Good Clinical Practice (GCP) standards. Twenty eligible healthy volunteers participated in the study following a thorough screening process.
All participants made three visits to the medical centre. During each visit, they consumed one of three test beverages sweetened with either sweelin, glucose, or stevia, in a crossover double-blind randomised controlled format. All beverages were matched for sweetness intensity, with the dosage aligned to the sweetness equivalent of 75 grams of glucose, similar to that used in a standard Oral Glucose Tolerance Test (OGTT). The study monitored the participant's responses to the test beverages for 120 minutes after consumption, measuring postprandial blood glucose and insulin levels.
